Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells 3,523 Shares of Stock

Key Points

• Ross Moat, an insider at Kiniksa Pharmaceuticals, sold 3,523 shares of the company's stock for a total of $124,397.13, reducing his ownership by 27.23%.
• Kiniksa Pharmaceuticals reported $0.23 earnings per share (EPS) for the last quarter, beating analysts' estimates, and had revenues of $156.80 million.
• Analysts have set a new target price for Kiniksa Pharmaceuticals, with recommendations ranging from $36.00 to $54.00, indicating a generally positive outlook on the stock.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) insider Ross Moat sold 3,523 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $35.31, for a total transaction of $124,397.13. Following the completion of the sale, the insider directly owned 9,415 shares of the company's stock, valued at approximately $332,443.65. The trade was a 27.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded up $0.09 during trading on Friday, hitting $37.10. The stock had a trading volume of 396,031 shares, compared to its average volume of 411,524. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of 927.73 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $37.34. The stock has a 50 day simple moving average of $31.86 and a 200 day simple moving average of $27.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on KNSA shares. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $41.17.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors have recently bought and sold shares of KNSA. EverSource Wealth Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after buying an additional 532 shares during the period. GAMMA Investing LLC increased its holdings in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares during the period. Osaic Holdings Inc. purchased a new position in Kiniksa Pharmaceuticals International during the second quarter valued at approximately $31,000. US Bancorp DE purchased a new position in Kiniksa Pharmaceuticals International during the first quarter valued at approximately $33,000. Finally, Asset Management One Co. Ltd. purchased a new position in Kiniksa Pharmaceuticals International during the first quarter valued at approximately $41,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.